March 2018, Volume 4, Issue 4

March 2018

Volume 4, Issue 4

This issue features a debate over whether CPX-351 can be used with other therapies in AML, a look at contract research organizations, and more.

Table of Contents

March 2018 Issue

Alice Ma, MD

Not What I Signed up For

Thursday, March 1st, 2018
Last month, while at a mandatory conference at our hospital and idly checking my email, a note from my nurse caught my attention: “Dr....
Dr. Yang (coach of the Ice Station Stars) and his son celebrate a recent win.

From the Ivory Tower to Corporate America

Thursday, March 1st, 2018
When I started in the MD/PhD program at a prestigious university in southern California, I was a 22-year-old straight out of college with few...

March 2018 Issue

MEI Develops Future Leaders, 2018 ASH-AMFDP Scholars Selected, and more

Thursday, March 1st, 2018
ASH Medical Educators Institute Develops Future Leaders The American Society of Hematology (ASH) Medical Educators Institute (MEI) develops future leaders in hematology education through...

Mohamad Cherry Joins Atlantic Health System, Remembering Eliezer A. Rachmilewitz, and more

Thursday, March 1st, 2018
Remembering Eliezer A. Rachmilewitz, MD Eliezer A. Rachmilewitz, MD, professor emeritus of medicine at the Hebrew University Hadassah Medical School in Jerusalem, died on December...

March 2018 Issue

Demystifying Zebrafish

Thursday, March 1st, 2018
Despite the vast sequencing data available to study the genetics of human disease, experimental animal models still play a critical role in unraveling the...

Contract Research Organizations: Outsourced Trials, Outsized Problems

Thursday, March 1st, 2018
A ranking of sorts is sent out every week to the chosen ones, but those who find themselves in the top spots don’t feel...

Teaching Old Drugs New Tricks?

Thursday, March 1st, 2018
When the U.S. Food and Drug Administration (FDA) approved CPX-351 (a fixed combination of daunorubicin and cytarabine), it appeared that everything old was new...

Pulling Back the Curtain: Andra James, MD, MPH

Thursday, March 1st, 2018
In this edition, Andra James, MD, MPH, shares how she became a specialist in hematology, obstetrics/gynecology, and even Civil War history. Dr. James is...

March 2018 Issue

What are the treatment options for a pregnant woman with chronic-phase CML?

Thursday, March 1st, 2018
This month Ayalew Tefferi, MD, discusses managing a pregnant patient with chronic-phase (CP) chronic myeloid leukemia (CML). And don't forget to check out next month's clinical...

March 2018 Issue

Firstline Eltrombopag Receives Breakthrough Designation for Severe Aplastic Anemia

Thursday, March 1st, 2018
The FDA granted breakthrough-therapy designation for firstline eltrombopag to treat severe aplastic anemia (SAA). The thrombopoietin receptor agonist received this designation based on research conducted...

Tax on Medical Devices Resumes After Two Years

Thursday, March 1st, 2018
In January, the 2.3 percent excise tax for medical devices was resumed, after a two-year hiatus. The tax was originally imposed in 2013 as...

IV Bag Shortage Making Flu Season Worse

Thursday, March 1st, 2018
Supplies of intravenous (IV) saline and nutrient solutions were already tight before hurricanes hit Puerto Rico in September of last year and cut power...

Mixed Results From SIMPLIFY-1 Complicate Myelofibrosis Treatment Decisions

Thursday, March 1st, 2018
The Janus kinase (JAK) inhibitor ruxolitinib is the only U.S. Food and Drug Administration–approved therapy for myelofibrosis (MF), but the resultant hematologic adverse events...

Combination Brentuximab Vedotin and Bendamustine Safe and Effective for Heavily Pretreated HL

Thursday, March 1st, 2018
Coupling the anti-CD30 antibody drug conjugate brentuximab vedotin with bendamustine may offer an effective salvage regimen for patients with relapsed/refractory Hodgkin lymphoma (HL), according...

Long-Term FOLL05-Up: R-CHOP Outperforms R-FM and R-CVP for Advanced-Stage Follicular Lymphoma

Thursday, March 1st, 2018
In 2005, the FOLL05 trial sought to determine the optimal immunochemotherapy (ICT) regimen for firstline treatment of advanced-stage follicular lymphoma (FL): R-CVP (rituximab, cyclophosphamide,...

Eltrombopag Reduces Thrombocytopenic Events in Patients With AML and MDS, But Not as Much...

Thursday, March 1st, 2018
Compared with placebo, the oral thrombopoietic receptor agonist eltrombopag significantly lowered the incidence of thrombocytopenic events in patients with acute myeloid leukemia (AML) or...

Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia

Thursday, March 1st, 2018
In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...
WIB_icon

Ibrutinib Plus R-ICE Induces Responses in Patients With Relapsed/Refractory DLBCL

Thursday, March 1st, 2018
A phase I study found that adding ibrutinib to R-ICE (rituximab, ifosfamide, carboplatin, etoposide) resulted in an overall response rate of 90 percent (range...
WIB_icon

Treatment With Blinatumomab Eradicates MRD in Patients with ALL

Thursday, March 1st, 2018
More than three-quarters of patients with acute lymphocytic leukemia (ALL) who were in complete remission (CR) following chemotherapy but still had evidence of minimal...
WIB_icon

Total Metabolic Tumor Volume Predictive of Survival in Patients With Hodgkin Lymphoma

Thursday, March 1st, 2018
Factors with prognostic significance in early-stage Hodgkin lymphoma (HL) include bulky disease, number of regions involved, advanced age, and the presence of B symptoms....
WIB_icon

Monitoring Pre-Malignant Clones May Predict Development of Therapy-Related Myeloid Neoplasms

Thursday, March 1st, 2018
Post-transplant development of therapy-related myeloid neoplasms (tMNs) originates in hematopoietic stem cells (HSCs) with tMN mutations that are present years before disease onset, according...

Study Claims Medicaid Changes Could Lead to Hospital Closures

Thursday, March 1st, 2018
Researchers are cautioning that undoing Medicaid expansions (which occurred under the ACA) may lead to hospital closures. Decreased Medicaid revenue would be to blame,...
WIB_icon

Ibrutinib Treatment May Predispose to Fungal Infections, Study Cautions

Thursday, March 1st, 2018
Although previous research has demonstrated that ibrutinib is associated with fewer infectious complications than standard chemotherapy in patients with chronic lymphocytic leukemia (CLL), a...

Study Confirms Risk of Breast Implant-Associated ALCL

Thursday, March 1st, 2018
After investigating 359 reports linking silicone and saline breast implants with the development of anaplastic large cell lymphoma (ALCL), the FDA found that women...

Denosumab Receives FDA Approval for the Prevention of Skeletal-Related Events in Those With MM

Thursday, March 1st, 2018
The FDA approved the sBLA for the RANK ligand inhibitor denosumab, expanding its indication to include the prevention of skeletal-related events (SREs) in patients...

FDA Grants Priority Review to Brentuximab Vedotin in Combination With AVD for Frontline Treatment...

Thursday, March 1st, 2018
The U.S. Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application (sBLA) for brentuximab vedotin in combination with AVD...

Three Corporate Giants Team Up to Disrupt Health Care

Thursday, March 1st, 2018
Amazon, Berkshire Hathaway, and JPMorgan Chase announced that they will form an independent health-care company for their employees in the U.S. The companies said the...

CDC Director Resigns Over Conflicts of Interest

Thursday, March 1st, 2018
Brenda Fitzgerald, MD, director of the Centers for Disease Control and Prevention (CDC), resigned from her appointment over financial conflicts of interest involving investments...

FDA Grants Priority Review to CAR T-Cell Therapy for DLBCL

Thursday, March 1st, 2018
The FDA granted priority review to the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for adults with relapsed/refractory diffuse large B-cell lymphoma who are...

FDA Approves Firstline Arsenic Trioxide for Acute Promyelocytic Leukemia

Thursday, March 1st, 2018
The FDA approved arsenic trioxide in combination with the all-trans retinoic acid (ATRA) tretinoin for firstline treatment of adults with newly diagnosed, low-risk acute...

SHARE